Tredje AP fonden Lowers Position in Abbott Laboratories $ABT

Tredje AP fonden cut its stake in shares of Abbott Laboratories (NYSE:ABT) by 25.1% during the 4th quarter, Holdings Channel.com reports. The fund owned 546,141 shares of the healthcare product maker’s stock after selling 183,010 shares during the period. Tredje AP fonden’s holdings in Abbott Laboratories were worth $68,426,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Larson Financial Group LLC lifted its stake in Abbott Laboratories by 5.2% during the 4th quarter. Larson Financial Group LLC now owns 16,866 shares of the healthcare product maker’s stock valued at $2,113,000 after acquiring an additional 835 shares in the last quarter. Handelsbanken Fonder AB raised its stake in Abbott Laboratories by 11.4% in the 4th quarter. Handelsbanken Fonder AB now owns 1,220,202 shares of the healthcare product maker’s stock valued at $152,879,000 after acquiring an additional 124,733 shares during the period. Hartford Funds Management Co LLC raised its stake in Abbott Laboratories by 68.5% in the 4th quarter. Hartford Funds Management Co LLC now owns 10,890 shares of the healthcare product maker’s stock valued at $1,365,000 after acquiring an additional 4,429 shares during the period. Integral Investment Advisors Inc. raised its stake in Abbott Laboratories by 30.0% in the 4th quarter. Integral Investment Advisors Inc. now owns 2,958 shares of the healthcare product maker’s stock valued at $371,000 after acquiring an additional 683 shares during the period. Finally, Profund Advisors LLC raised its stake in Abbott Laboratories by 25.9% in the 4th quarter. Profund Advisors LLC now owns 28,291 shares of the healthcare product maker’s stock valued at $3,545,000 after acquiring an additional 5,822 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company lowered their price objective on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Jefferies Financial Group lowered their price objective on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Bank of America lowered their price objective on Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Argus lowered their price objective on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Finally, TD Cowen reduced their target price on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $119.43.

Abbott Laboratories Stock Up 4.0%

ABT stock opened at $87.82 on Tuesday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $152.96 billion, a PE ratio of 24.60, a PEG ratio of 1.41 and a beta of 0.65. The stock has a 50-day simple moving average of $98.56 and a two-hundred day simple moving average of $112.98.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same quarter in the previous year, the firm earned $1.09 earnings per share. Abbott Laboratories’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.9%. Abbott Laboratories’s payout ratio is presently 70.59%.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares of the company’s stock, valued at $12,053,953.78. The trade was a 0.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock valued at $353,097 in the last ninety days. Insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.